Two NIAID-supported Consortia, the Scripps CHAVD and the Duke CHAVD, in conjunction with the NIAID intramural Vaccine Research Center and the HIV Vaccine Trials Network, have established the Collaborative HIV Immunogen Project (CHIP) to leverage NIAID resources and to speed development of a protective HIV vaccine.
The overall goals of the CHIP are to coordinate efforts, streamline workflows, and establish the feasibility of an HIV-neutralizing antibody-based vaccine by allowing the major HIV vaccine programs to harmonize development strategies. Other HIV vaccine stakeholders are encouraged to consider this collaboration and bridge with this unified effort in facing the many scientific challenges ahead.